CSL LIMITED
ASX:CSLPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 99.7% of what they think they own, once every option and right converts.
No major dilution pressure signals in current disclosures
CSL LIMITED's ordinary share count was 480M as of September 2026, down 0.9% from September 2024. The company did not raise capital in the past 24 months and has no pending proposed securities issues. Options and rights on issue could convert into 2M new shares, representing 0.3% of the current share count, with no stated expiry date. The company has not lodged a current quarterly cash report, so no cash balance or funding-runway figure is disclosed on that basis.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 8 Sept 2026 | 3G · unquoted | CSL : ORDINARY FULLY PAID | 479.7M | Appendix 3G |
| 8 Sept 2026 | 2A · quoted issue | CSL : ORDINARY FULLY PAID | 479.9M | Appendix 2A |
| 7 Sept 2026 | 3H · cancellation | CSL : ORDINARY FULLY PAID | 479.7M | Appendix 3H |
| 3 Sept 2026 | 3G · unquoted | CSL : ORDINARY FULLY PAID | 478.9M | Appendix 3G |
| 3 Sept 2026 | 2A · quoted issue | CSL : ORDINARY FULLY PAID | 479.7M | Appendix 2A |
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 1.7M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| CSLAL | Rights | Condition-triggered | — | — | 1.7M | Filing Meeting |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 26 Aug 2026 | Dr Brian McNamee AO | Other | — | 6k | — | $951k | 3Y notice |
| 26 Aug 2026 | Mr Brian Daniels | Other | — | 317 | — | $54k | 3Y notice |
| 26 Aug 2026 | Mr Cameron Bruce Price | Other | — | 2k | — | $268k | 3Y notice |
| 26 Aug 2026 | Mr Constantine Saroukos | Other | — | 2k | — | $268k | 3Y notice |
| 26 Aug 2026 | Ms Alison Watkins AM | Other | — | — | 523 | $88k | 3Y notice |
| 26 Aug 2026 | Ms Carolyn Hewson AO | Other | — | 475 | — | $80k | 3Y notice |
| 26 Aug 2026 | Ms Elaine Sorg | Other | 317 | — | — | $54k | 3Y notice |
| 26 Aug 2026 | Ms Samantha Lewis | Other | — | 793 | — | $134k | 3Y notice |
| 26 Aug 2026 | Professor Robert Andrew Cuthbertson AO | Other | — | — | 2k | $268k | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.